Reference is made to the stock exchange announcement made by Nordic Nanovector ASA on 6 June 2023 regarding the Company’s acquisition of Thor Medical AS, with approval of the Transaction from the Company’s annual general meeting as one of the closing conditions.
OSLO, Norway, June 28, 2023 /PRNewswire/ -- Reference is made to the stock exchange announcement made by Nordic Nanovector ASA (“Nordic Nanovector” or the “Company”) on 6 June 2023 regarding the Company’s acquisition of Thor Medical AS (the “Transaction”), with approval of the Transaction from the Company’s annual general meeting (the “AGM”) as one of the closing conditions.
Please find attached the minutes from the AGM. All items on the agenda were approved by the AGM, including the agenda items relating to the Transaction.
The Transaction is expected to be consummated on or around 3 July 2023.
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Ludvik Sandnes, Interim CEO & CFO
Cell: +47 907 43 017
Email: ir@nordicnanovector.com
The following files are available for download:
| NANOV - OGF protokoll m_fremmøte - 28. juni 2023(1989561.1) |
View original content:https://www.prnewswire.com/news-releases/nordic-nanovector--completion-of-annual-general-meeting-301865939.html
SOURCE Nordic Nanovector
Company Codes: Bloomberg:NANOV@NO, ISIN:NO0010597883, Oslo:NANOV, RICS:NANOV.OL, Stockholm:NANOO
